IOTA Pharmaceuticals

Email Usinfo@iotapharma.com

IOTA Pharmaceuticals

 
Fragment - based Drug Discovery
Neglected Parasitic Disease
Glioma & Glioblastoma
 
 
About IOTA Pharmaceuticals
Home
IOTA Pharmaceuticals has been established to bring you the tools and technologies for fragment-based drug discovery.
About Us
IOTA is a new-style pharmaceutical discovery services company. Built around the scientific expertise and industrial experience of its Founder Investors, and leveraged by networked resources, IOTA possesses a wealth of discovery knowledge and experience which we place at your disposal.
Products
IOTA currently offers a unique "Diverse 1500" fragment Library, in a number of formats, dispatched as pre-weighed, dry powders in individually sealed tubes
Services
IOTA offers the following Screening Services:
Virtual screening packages
Surface Plasmon Resonance (SPR) screening package
High-sensitivity biochemical screening package
Nuclear Magnetic Resonance (NMR) screening package
Co-crystallography of Fragment-based leads
Resources
We have created IOTA specifically to serve researchers in the emerging area of fragment-based drug discovery.
Contact Us
IOTA Pharmaceuticals Ltd
St Johns Innovation Centre
Cowley Road
Cambridge
CB4 0WS
United Kingdom

:

+44 (0) 1223 421430

:

+44 (0) 1223 421430

:

info@iotapharma.com

IOTA Design
IOTA’s UK Design Labs are based in the IT-leading University city of Cambridge.
IOTA Screening
Through its co-Founder, Dr Paul England, IOTA has considerable experience in high-sensitivity, high-throughput compound screening, both at the biochemical and functional, cell-based level.
IOTA Chemistry
In addition to IOTA’s own in-house organic chemistry and drug discovery capabilities in Amsterdam, we have strong links with the emerging chemistry company, Oxygen Healthcare.
IOTA Discovery
IOTA has a close working relationship with the Department of Medicinal Chemistry at the Free University of Amsterdam.
Business Development
IOTA’s Business Development offices are based in the St Johns Innovation Centre in Cambridge, Europe’s leading biotech city. Web-focussed, we offer business connectivity in the fragment-based drug design area to drug discovery companies, large and small.
IOTA Diverse 1500
 
IOTA-Vitas 4000
 
FBDD Screening Services
 
Diverse 1500 Fragment Library
IOTA currently offers a unique "Diverse 1500" fragment Library, in a number of formats, dispatched as pre-weighed, dry powders in individually sealed tubes
RSS

22-Feb-2011

IOTA announces KINOMED, a new partnership

17-Aug-2009

New consortium to develop drugs for neglected tropical diseases

23-Apr-2008

IOTA announces SPR initiative with Beactica AB

Read more